Advertisement

Zeitschrift für Rheumatologie

, Volume 76, Issue 2, pp 111–117 | Cite as

Evidenzbasierte Empfehlung zur Diagnostik und Therapie der axialen Spondyloarthritis

S3-Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh) in Kooperation mit der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)
Leitthema

Zusammenfassung

Der klinische Verlauf der axialen Spondyloarthritis (axSpA) ist variabel und durch chronische Rückenschmerzen und extraspinale Manifestationen wie asymmetrische Oligoarthritis, Enthesitis und Daktylitis gekennzeichnet. Nicht wenige Patienten haben auch extraartikuläre Manifestationen an Augen (anteriore Uveitis), Haut (Psoriasis) oder Darm (chronisch entzündliche Darmerkrankungen). Durch die Heterogenität des klinischen Bildes und die Konzentration auf röntgenologisch sichtbare strukturelle Veränderungen in den Sakroiliakalgelenken ist es zu einer zum Teil erheblichen Verzögerung von mehreren Jahren bei der Diagnosestellung gekommen. Ein wichtiger Schritt in Richtung einer verbesserten Früherkennung waren die 2009 publizierten Assessment of SpondyloArthritis International Society (ASAS)-Klassifikationskriterien für axSpA, die neben der Chronizität der initial meist tief sitzenden Rückenschmerzen bei noch relativ jungen Menschen sowohl die Bedeutung der Magnetresonanztomographie als auch die Bestimmung von HLA-B27 in frühen Phasen der Erkrankung betonen. Um die Grundlagen für eine effektive und frühzeitige Therapie der betroffenen Patienten zu gewährleisten, ist dann im Jahr 2014 auf Initiative der Deutschen Gesellschaft für Rheumatologie (DGRh) eine S3-Leitlinie „Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen“ unter Mitwirkungen vieler anderer Fachgesellschaften erstellt worden. Dieser Beitrag gibt einen Überblick über den Inhalt der S3-Leitlinie zur axSpA.

Schlüsselwörter

Management Ankylosierende Spondylitis Enthesitis Daktylitis Magnetresonanztomographie 

Evidence-based recommendations on diagnostics and therapy of axial spondyloarthritis

S3 guidelines of the German Society of Rheumatology (DGRh) in cooperation with the Association of the Scientific Medical Societies in Germany (AWMF)

Abstract

The clinical course of axial spondyloarthritis (SpA) is variable and characterized by chronic back pain and extraspinal manifestations, such as asymmetrical arthritis, dactylitis and enthesitis. Extra-articular manifestations in the eyes (anterior uveitis), skin (psoriasis) and intestines (chronic inflammatory bowel disease) are also frequent manifestations in patients with SpA. Due to the heterogeneity of disease manifestations and the partial concentration on structural alterations in the sacroiliac joints visible in X‑ray images, the diagnosis is often delayed for many years. An important step in the direction of improved early recognition of axial SpA was establishment of the Assessment of SpondyloArthritis International Society (ASAS) classification criteria published in 2009, which focused on the initally deep-seated back pain and chronicity in relatively young patients as well as the importance of magnetic resonance imaging and HLA B 27 determination in the early stages of the disease. In order to achieve the foundations for an effective and timely therapy of affected patients, in 2014 on the initiative of the German Society of Rheumatology, S3 guidelines on axial SpA including Bechterew’s disease and early forms were formulated in cooperation with other specialist societies. This article gives an overview of the contents of the S3 guidelines on axial SpA.

Keywords

Management Ankylosing spondylitis Enthesitis Dactylitis Magnetic resonance imaging 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

Die bestehenden Interessenskonflikte der Leitlinienautoren für die Erstellung der S3-Leitlinie sind im Leitlinien-Report ausführlich dargestellt.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Bohle E et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 1 Introduction/preliminary comments. Z Rheumatol 73(Suppl 2):23–25CrossRefPubMedGoogle Scholar
  2. 2.
    Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 377(9783):2127–2137CrossRefPubMedGoogle Scholar
  3. 3.
    Kiltz U, Oberschelp U, Schneider E, Swoboda B, Bohm H, Winking M et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 8.6 Invasive therapy. Z Rheumatol 73(Suppl 2):97–100CrossRefPubMedGoogle Scholar
  4. 4.
    Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMedGoogle Scholar
  5. 5.
    Kiltz U, Rudwaleit M, Sieper J, Krause D, Chenot JF, Stallmach A et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 3 Clinical symptoms. Z Rheumatol 73(Suppl 2):28–39CrossRefPubMedGoogle Scholar
  6. 6.
    Kiltz U, Rudwaleit M, Sieper J, Krause D, Heiligenhaus A, Pleyer U et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 5 Initial diagnosis/referral strategy. Z Rheumatol 73(Suppl 2):44–48CrossRefPubMedGoogle Scholar
  7. 7.
    Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369(9570):1379–1390CrossRefPubMedGoogle Scholar
  8. 8.
    van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368CrossRefPubMedGoogle Scholar
  9. 9.
    Zink A, Braun J, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis – results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27(3):613–622PubMedGoogle Scholar
  10. 10.
    Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H et al (2009) The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60(3):717–727CrossRefPubMedGoogle Scholar
  11. 11.
    Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J et al (2012) Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 64(5):1388–1398CrossRefPubMedGoogle Scholar
  12. 12.
    Kiltz U, Rudwaleit M, Sieper J, Krause D, Hermann KG, Braun J (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 6 Diagnostics. Z Rheumatol 73(Suppl 2):49–65CrossRefPubMedGoogle Scholar
  13. 13.
    Montala N, Juanola X, Collantes E, Munoz-Gomariz E, Gonzalez C, Gratacos J et al (2011) Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. J Rheumatol 38(5):893–897CrossRefPubMedGoogle Scholar
  14. 14.
    Song IH, Carrasco-Fernandez J, Rudwaleit M, Sieper J (2008) The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis 67(11):1535–1540CrossRefPubMedGoogle Scholar
  15. 15.
    Dougados M, Gueguen A, Nakache JP, Velicitat P, Zeidler H, Veys E et al (1999) Clinical relevance of C‑reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 26(4):971–974PubMedGoogle Scholar
  16. 16.
    Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H et al (1999) Relative value of erythrocyte sedimentation rate and C‑reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26(4):980–984PubMedGoogle Scholar
  17. 17.
    Kiltz U, Sieper J, Rudwaleit M, Kellner H, Krause D, Bohle E et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 8 Therapy, 8.1 Treatment concept, 8.2 Therapy targets and strategy. Z Rheumatol 73(Suppl 2):69–70CrossRefPubMedGoogle Scholar
  18. 18.
    Kiltz U, Mau W, Smolenski U, Repschlager U, Bohle E, Stemmer M et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 8.3 Nonpharmaceutical therapeutic measures. Z Rheumatol 73(Suppl 2):71–77CrossRefPubMedGoogle Scholar
  19. 19.
    Kiltz U, Sieper J, Kellner H, Krause D, Rudwaleit M, Chenot JF et al (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures. Z Rheumatol 73(Suppl 2):78–96CrossRefPubMedGoogle Scholar
  20. 20.
    van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R et al (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70(6:905–908CrossRefGoogle Scholar
  21. 21.
    Kiltz U, Sieper J, Braun J (2013) ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area. Z Rheumatol 72(1:81–88CrossRefGoogle Scholar
  22. 22.
    Chen J, Liu C (2005) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2:CD004800Google Scholar
  23. 23.
    Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K et al (2006) Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 65(9):1147–1153CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chen J, Liu C, Lin J (2006) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD004524Google Scholar
  25. 25.
    Vander Cruyssen B, Munoz-Gomariz E, Font P, Mulero J, de Vlam K, Boonen A et al (2010) Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford) 49(1):73–81CrossRefGoogle Scholar
  26. 26.
    Kiltz U, Mau W, Repschlager U, Bohle E, Braun J (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 8.7 Rehabilitation. Z Rheumatol 73(Suppl 2):101–103CrossRefPubMedGoogle Scholar
  27. 27.
    Kiltz U, Mau W, Repschlager U, Bohle E, Braun J (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 9 International classification of functioning, disability and health (ICF). Z Rheumatol 73(Suppl 2):104–108CrossRefPubMedGoogle Scholar
  28. 28.
    Boonen A, Braun J, van der Horst Bruinsma IE, Huang F, Maksymowych W, Kostanjsek N et al (2010) ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis 69(1):102–107CrossRefPubMedGoogle Scholar
  29. 29.
    Kiltz U, Stemmer M, Braun J (2014) German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew’s disease and early forms: 10 Patient information. Z Rheumatol 73(Suppl 2):109–111CrossRefPubMedGoogle Scholar
  30. 30.
    Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P et al (2015) Secukinumab, an Interleukin-17A Inhibitor. N Engl J Med 373(26):2534–2548CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Rheumazentrum RuhrgebietHerneDeutschland
  2. 2.Klinik RosenhöheKlinikum BielefeldBielefeldDeutschland
  3. 3.Campus Benjamin-FranklinCharitéBerlinDeutschland

Personalised recommendations